Transforming the Diagnosis and Management of Preeclampsia 

Click here to watch the video

Learn more about Carmenta.

Watch the Video.

Current News 

Progenity Acquires Carmenta Bioscience for Proprietary Preeclampsia Technology; Appoints Matthew Cooper Chief Scientific Officer

Carmenta CEO, Matthew Cooper, heralds recent developments in Alnylam's new drug for preeclampsia in the latest issue of SciBx.

Life Science Angels Ranked the Top Angel Investment Group in the U.S.

Read more News